U.S. stock market update: Pheton down 7.82%

U.S. Stock Market Midday Update Pheton fell 7.82%, with increased trading volume. According to recent important news: On July 31, Huace Testing had a block trade of 7.4917 million shares, with a transaction amount of 93.3466 million yuan, accounting for 18.05% of the total transaction amount that day, with a transaction price at a premium of 2.38% compared to the market closing price, attracting market attention and causing stock price fluctuations. On July 31, Guoxuan High-Tech had a block trade of 2.3496 million shares, with a transaction amount of 69.5233 million yuan, accounting for 4.77% of the total transaction amount that day, with a transaction price at a premium of 1.23% compared to the market closing price, affecting market sentiment. On July 30, Saifen Technology saw a net outflow of 8.9098 million yuan in main funds, accounting for 1.1% of the circulating market value, putting pressure on the stock price. Stocks with High Trading Volume in the Industry Veeva Systems fell 0.86%, with increased trading volume. According to recent key news: On July 31, Veeva Systems released a press release containing forward-looking statements, mentioning several risk factors that could impact the company's performance, leading to increased market concerns about its future performance, and the stock price fell by 0.86%. On August 1, MarketBeat reported that although Veeva Systems was rated as "Moderate Buy," top analysts were more optimistic about five other stocks, which weakened investor confidence. On July 30, Veeva Systems disclosed risks and uncertainties in its 10-Q filing as of April 30, 2025, further exacerbating market concerns about its future performance. Doximity fell 1.96%, with increased trading volume. Based on recent key news: On July 31, Doximity released the 2025 Physician Compensation Report, showing a salary growth of only 3.7% and revealing a 26% gender pay gap. These data reflect ongoing pressures in the healthcare industry, leading to a decline in investor confidence and a 1.96% drop in stock price. On July 31, Doximity's Chief Medical Officer Amit Phull pointed out that concerns over reduced reimbursements for pediatricians have heightened market worries about the company's future profitability, further pressuring the stock price. On July 31, the report released by Doximity mentioned the challenges and pressures faced by healthcare professionals, increasing market doubts about the company's business growth, leading to a drop in stock price. Teladoc fell 1.80%, with increased trading volume. Based on recent key news: On July 30, Teladoc announced its second-quarter financial report, with revenue of $631.9 million, exceeding expectations, and a loss of $0.19 per share, better than the expected $0.25. Despite the better-than-expected performance, the market outlook remains pessimistic, leading to a decline in stock price On July 30, Teladoc's management emphasized progress in product innovation and operational efficiency but noted challenges in the U.S. direct-to-consumer mental health sector, leading to a negative market reaction. On July 30, analysts predicted limited revenue growth for 2026/27, with only an increase of $100 million, causing the market to be skeptical about the company's future growth potential, further pressuring the stock price. Stocks ranked among the top in industry market capitalization Waystar fell 3.41%, with increased trading volume. According to recent important news: On July 30, Waystar released its second-quarter financial report, with GAAP revenue reaching $270.7 million, exceeding expectations by $11.17 million, but the stock price failed to rise and instead dropped by 3.41%. On July 31, analysts set a 12-month target price for Waystar at $49.50, which is 27.9% higher than the current stock price, but this did not boost market confidence. On August 1, concerns about Waystar's revenue structure changes and integration execution intensified, leading to pressure on the stock price